研究团队还进行了一项前瞻性临床试验，结果显示，L-鸟氨酸可显著提升乌司奴单抗在克罗恩病患者中的治疗效果。该研究首次建立了“微生物-代谢物-免疫靶点”调控网络，为炎症性肠病（IBD）的 精准 治疗提供新策略。

Samsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...

该研究是由上海交通大学医学院附属仁济医院消化科研究员洪洁及其团队主导，论文共同第一作者为仁济医院消化科硕士研究生王振宇，博士研究生蒋怡、宁立军，四川省人民医院消化内科医师、博士后朱小强以及中南大学湘雅三医院消化内科主任医师田力。中南大学湘雅三医院消化 ...

Better cardiovascular safety and lower risk of all-cause mortality was observed among older adult patients with IBD who received ustekinumab vs vedolizumab.

Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesKey biosimilar value driver contributes to Sandoz global growth strategy ...

YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.

YESINTEK is approved for Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering a ...

Biocon share rose after Biocon Biologics, a subsidiary of Biocon, announced that Yesintek (ustekinumab-kfce) is now available ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...

Ltd. today announced that PYZCHIVA® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is now available in the United States. PYZCHIVA has been approved for the treatment of moderate to ...